OEM overview
Custom peptide microneedle patch development for targeted anti-wrinkle and firming cosmetic concepts. Each program is reviewed for cosmetic category, technical feasibility, target-market rules and manufacturability before samples begin.
Formula and active options
Potential directions include acetyl hexapeptide-8, copper peptide and multi-peptide concepts. Final composition, active level, compatibility and claims depend on the agreed specification, stability strategy and destination market.
Cosmetic positioning
Programs may be positioned for fine-line appearance, hydration, firmness and targeted care. We avoid medical or drug claims unless the customer establishes a separate, appropriately authorized development pathway.
Customization options
OEM / private-label workflow
- Submit product brief, target market, volume and timing.
- Confirm technical assumptions, sample scope and commercial pathway.
- Develop or adapt formula and patch geometry.
- Evaluate samples against agreed appearance, handling and dissolution criteria.
- Align packaging, pilot plan, specifications and production documents.
Cosmetic peptide platform selection
For ingredient-led projects, compare GHK-Cu copper peptide, Acetyl Hexapeptide-8, palmitoyl peptide and multi-peptide routes. Selection follows compatibility, intended cosmetic positioning, analytical needs and destination-market review.
GLP-1 receptor agonists are drug actives, not interchangeable with cosmetic peptides. Review our GLP-1 and Retatrutide microneedle patch compliance guide before submitting an ingredient brief.
Peptide eye-patch configuration
Peptide eye patch
- Array material
- Hyaluronic acid (HA)
- Nominal needle height
- 300–1,000 µm
- Needles per patch
- 750
- Customization
- Size and color
Peptide eye configuration
Ingredient reference: Acetyl Hexapeptide-8, Hexapeptide-9 and Tripeptide-1
Cosmetic eye-area appearance development
Portfolio pp. 12
Questions buyers ask before the next step
The following answers convert this page into a decision-ready reference rather than a general marketing summary. Each answer states the conclusion first and then names the variables that can change it. Numerical values such as MOQ, lead time, active content, dimensions, shelf life and price are not presented as universal facts when they depend on an unapproved project specification. This makes the page easier for both human buyers and AI systems to quote accurately: confirmed company or process information remains separate from product-specific assumptions, while cosmetic, medical and jurisdictional boundaries stay visible. For a live project, use these answers to prepare the brief and request the supporting specification, test or contractual record. Mark unresolved inputs as open actions with an owner and due date, then update the controlled project version after evidence is reviewed.
Is Peptide Microneedle Patches OEM a ready-stock product?
This page describes a potential custom cosmetic development direction, not guaranteed ready inventory. Formula, active level, array geometry, backing, packaging, MOQ, lead time, evidence and target-market acceptability must be confirmed for the buyer’s approved brief.
Which specifications should be confirmed before sampling?
Confirm ingredient identity and target content basis, matrix and patch dimensions, needle geometry, application area, backing and pouch system, appearance and handling criteria, dissolution method, storage conditions, desired shelf life and claims direction. Record the sample version so feedback is traceable.
Which claims can the finished patch use?
Claims must remain consistent with the product category and be supported for the finished product as presented and used. Ingredient studies do not automatically substantiate the patch. Avoid treatment, disease, structural or drug-delivery claims unless a separate qualified regulatory pathway has been established.
Content review: Last reviewed October 15, 2026. Material changes to formula, claims, manufacturing scope or target market require a fresh review.